The U.S. FDA has approved California-based Amgen’s chronic heart-failure treatment, Corlanor.
According to Amgen, Corlanor is the first new chronic heart failure medicine approved by the FDA in nearly a decade.
The drug is an oral medication indicated to reduce the risk of hospitalization for worsening heart failure in a specific subset of patients.
The NY Times claims that analysts and heart failure specialists are "lukewarm" about the new drug, and are more hopeful about Novartis' heart failure drug, LCZ696, slated to be approved late this summer.
Read the Amgen press release.